Algernon finishes ifenprodil phase 2b with last patient
2020-12-24 12:10 ET - News Release
Mr. Christopher Moreau reports
ALGERNON PHARMACEUTICALS ANNOUNCES LAST PATIENT OUT IN MULTINATIONAL PHASE 2B/3 HUMAN STUDY OF IFENPRODIL FOR COVID-19
The last patient from Algernon Pharmaceuticals Inc.'s phase 2b part of its multinational phase 2b/3 human study of NP-120 (ifenprodil) for the treatment of COVID-19 has now completed treatment, as well as the required two-week follow up.
The Company announced positive trending interim data for the Phase 2b part of it Phase 2b/3 Ifenprodil COVID-19 Study, on December 15, 2020. The Company is projecting the final data set will be available before the end of February, 2020.
"This is another important step for the Company," said Christopher J. Moreau, CEO of Algernon Pharmaceuticals. "Now that we have announced final patient out of the Ifenprodil COVID-19 study, we can begin preparations for the final data report."
The Company advises that it is not making any express or implied claims that Ifenprodil has the ability to eliminate, cure or contain COVID-19 (or the SARS-2 Coronavirus) at this time.